Lawsuits against drugmakers have been piling up since the organic compounds, which are commonly found in water and food, caused numerous drug recalls. As the FDA continues to investigate the potential link between nitrosamines and the risk of cancer, some of the first trials are set for 2023, and pharmaceutical companies could end up paying $45 billion.
Here are the six drugs that have been recalled because of nitrosamine impurities in 2022:
1. Viona Pharmaceuticals recalled 23 lots of metformin hydrochloride extended release tablets.
2. Sandoz recalled 13 lots of orphenadrine citrate 100 mg extended release tablets.
3. Pfizer and its subsidiary Greenstone recalled 11 lots of Accuretic (quinapril/hydrochlorothiazide) tablets.
4. Pfizer recalled five lots of hypertension drug Accupril.
5. Aurobindo Pharma USA recalled two lots of quinapril and hydrochlorothiazide tablets.
6. Lupin recalled four lots of quinapril 20 mg and 40 mg tablets.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.